Sotera Health Company (SHC) Cash Flow Statement

The conversion ratio has been volatile, ranging from negative in Q1 2025 to above 7x in several 2024 and 2025 quarters, which points to large non-cash charges such as intangible amortization and litigation accruals distorting reported net income. Investors should view the consistently positive operating cash flow as the more reliable signal of earnings power, while recognizing that the ratio's extremes warrant further investigation into the timing of accrual reversals. The Q1 2026 OCF/NI of 1.11, with working capital drawing $46.1M, suggests that cash conversion can weaken sharply when working capital absorbs funds.

The swing from negative FCF to a double-digit margin within two quarters is largely attributable to working capital normalization rather than a structural step-up in operating economics, as the Q1 2026 working capital outflow of $46.1M reversed in subsequent periods. The FCF margin in Q4 2025 of 17.3% and Q3 2024 of 20.7% indicates the business can sustain high cash margins, but the 2024Q4 negative FCF margin of -3.5% shows that capital spending spikes can erase that capacity in individual quarters. Investors should monitor whether the recovery holds once CapEx normalizes, since the 2024Q4 CapEx/Revenue of 22.7% demonstrates how lumpy investment can compress reported FCF.

The CapEx/Revenue ratio of 16.3% in the latest quarter sits well above what would be typical for a pure services model, reflecting the specialized irradiation and chemical processing infrastructure that the business requires. The data does not separate maintenance from growth capital, so it is unclear how much of this spending is required simply to sustain existing sterilization capacity versus expanding it. Given the potential for EPA NESHAP requirements to add emission-control spending, investors should consider whether the current intensity is a floor or whether regulatory retrofits could push it materially higher.

The absence of dividends and the near-absence of buybacks suggests that management is prioritizing balance sheet flexibility and debt management over shareholder distributions, consistent with the elevated leverage profile. The data does not show the use of free cash flow for debt paydown in detail, so the precise allocation of retained cash remains uncertain. Investors should monitor whether accumulated FCF is applied to deleveraging or held against potential litigation settlements and compliance spending.